Business Context and Reporting Period
This Form 8-K, filed on May 12, 2011, by RXi Pharmaceuticals Corporation (now SELLAS Life Sciences Group, Inc.), reports financial results for the quarter ended March 31, 2011, and significant corporate developments. The company is a biotechnology firm focused on RNA-targeted and immunotherapy technologies. Key events during this period include the acquisition of Apthera, Inc. on April 13, 2011, and two public equity offerings in March and April 2011.
Key Financial Metrics
| Metric | Value |
|---|---|
| Net Loss (Q1 2011) | $3,841,000 |
| Cash Used in Operating Activities (Q1 2011) | $3,027,000 |
| Research and Development Expense (Q1 2011) | $2,156,000 |
| General and Administrative Expense (Q1 2011) | $3,118,000 |
| Cash and Cash Equivalents (as of March 31, 2011) | $11.1 million |
| Cash and Cash Equivalents (as of April 30, 2011) | $19.6 million |
| Net Proceeds from March 2011 Offering | $7.3 million |
| Net Proceeds from April 2011 Offering | $10.9 million |
The filing does not provide revenue figures, gross margins, or specific debt balances, as the company is in a pre-revenue development stage.
Material Changes Versus Prior Period
- Net Loss: The net loss for the three months ended March 31, 2011, was $3,841,000. This includes significant non-cash charges: $1,314,000 in stock-based compensation, $1,435,000 related to the fair value of warrants and mandatorily redeemable stock obligations, and $76,000 in stock warrant expense.
- Operating Cash Flow: Net cash used in operating activities increased to $3,027,000 from $2,444,000 in the same period in 2010.
- R&D Expenses: Increased by $230,000 (12%) to $2,156,000, driven by a $442,000 increase in ocular and dermal anti-scarring studies, partially offset by a decrease in non-cash share-based compensation.
- G&A Expenses: Increased by $588,000 (23%) to $3,118,000. Excluding non-cash items, G&A expenses were $1,919,000 compared to $1,448,000 in the prior year.
- Liquidity: Cash position improved significantly from $11.1 million at March 31, 2011, to $19.6 million by April 30, 2011, following the April equity offering.
Guidance, Outlook, and Risks
- Acquisition Impact: The acquisition of Apthera, Inc. added NeuVax (E75), a late-stage immunotherapy for breast cancer, to the pipeline. Phase III trials are slated to commence in the first half of 2012 under an FDA Special Protocol Assessment (SPA).
- Pipeline Development: RXI-109, a self-delivering RNAi product for anti-scarring, is scheduled to commence human clinical trials in early 2012. An Investigational New Drug (IND) application is targeted for submission in the second half of 2011.
- Scientific Progress: Collaboration with Generex Biotechnology showed success in silencing genes up to 80% in hemopoietic cells using proprietary sd-rxRNA compounds.
- Corporate Governance: The company temporarily failed to comply with NASDAQ Marketplace Rule 5605 due to a resignation from the Audit Committee. Compliance was regained on May 16, 2011, following the appointment of a new independent director.
- Risks: The filing includes standard forward-looking statement disclaimers regarding the uncertainty of clinical trial results, regulatory approvals, and the ability to secure future financing.
Investor Verification Checklist
- Verify the closing status and final net proceeds of the April 2011 public offering.
- Confirm the timeline for the submission of the IND application for RXI-109.
- Review the specific terms of the FDA Special Protocol Assessment (SPA) for NeuVax Phase III trials.
- Monitor the company's cash burn rate relative to the $20 million pro forma cash position to assess runway for clinical trials.
- Check for any updates on the composition of the Audit Committee to ensure continued NASDAQ compliance.